Sign up to get updates from us
Dr. Coffey explains how a phenomenon first observed over a 100 years ago – that a systemic infection can cure cancer – became the blanket term for a treatment modality bearing his company’s name. From being a lab rat studying reovirus one day, to a company co-founder the next, Coffey’s rise through the corporate ranks (he started out as VP of Product Development), and his pursuit of the scientific secrets that revealed the true activity of his lead asset (hint: lysing tumor cells ain’t it) set Oncolytics on the path to achieving medicine’s ultimate goal: teaching a patient’s immune system to kill cancer.
Topics on the show include:
•Why a scientist might need an MBA
•The MOA of reovirus
•Intratumoral vs. systemic administration of virus
•Wild type vs. engineered virus from a regulatory perspective
•Clinical programs for Pelareorep (reovirus)
•The bacchanalia that is the Calgary Stampede…
